177 related articles for article (PubMed ID: 36335460)
1. Analysis of response of severe eosinophilic asthmatic patients to benralizumab.
Miralles-López JC; Andújar-Espinosa R; Bravo-Gutiérrez FJ; Castilla-Martínez M; Flores-Martín I; Alemany-Francés ML; Pajarón-Fernández MJ; Mora-González A; Cabrejos-Perotti S; El-Molaka Z; Meseguer-Arce J; Avilés-Inglés MJ; Valverde-Molina J; Pérez-Fernández V;
Allergol Immunopathol (Madr); 2022; 50(6):163-168. PubMed ID: 36335460
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study.
Bravo-Gutiérrez FJ; Miralles-López JC; Valverde-Molina J; Alemany Francés ML; Andújar-Espinosa R; Castilla-Martínez M; Avilés-Inglés MJ; Mora-González A; Pajarón-Fernández MJ; Cabrejos-Perotti S; Meseguer-Arce J; Flores Martín I; Pérez-Fernández V;
Int Arch Allergy Immunol; 2024; 185(3):253-259. PubMed ID: 38035559
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study.
Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
Int Arch Allergy Immunol; 2023; 184(8):736-743. PubMed ID: 36996772
[TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.
Kavanagh JE; Hearn AP; Dhariwal J; d'Ancona G; Douiri A; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Kent BD; Jackson DJ
Chest; 2021 Feb; 159(2):496-506. PubMed ID: 32882249
[TBL] [Abstract][Full Text] [Related]
5. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
Canonica GW; Harrison TW; Chanez P; Menzella F; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; Garcia Gil E
Allergy; 2022 Jan; 77(1):150-161. PubMed ID: 33978983
[TBL] [Abstract][Full Text] [Related]
6. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.
Vultaggio A; Aliani M; Altieri E; Bracciale P; Brussino L; Caiaffa MF; Cameli P; Canonica GW; Caruso C; Centanni S; D'Amato M; De Michele F; Del Giacco S; Di Marco F; Menzella F; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Benci M; Boarino S; Schroeder JW
Respir Res; 2023 May; 24(1):135. PubMed ID: 37210543
[TBL] [Abstract][Full Text] [Related]
7. Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma.
Yamada H; Nakajima M; Matsuyama M; Morishima Y; Arai N; Hida N; Nakaizumi T; Masuko H; Yatagai Y; Saito T; Hizawa N
PLoS One; 2021; 16(3):e0248305. PubMed ID: 33705484
[TBL] [Abstract][Full Text] [Related]
8. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
[TBL] [Abstract][Full Text] [Related]
9. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.
Menzies-Gow A; Hoyte FL; Price DB; Cohen D; Barker P; Kreindler J; Jison M; Brooks CL; Papeleu P; Katial R
Adv Ther; 2022 May; 39(5):2065-2084. PubMed ID: 35287231
[TBL] [Abstract][Full Text] [Related]
10. Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study.
Nolasco S; Crimi C; Pelaia C; Benfante A; Caiaffa MF; Calabrese C; Carpagnano GE; Ciotta D; D'Amato M; Macchia L; Pelaia G; Pellegrino S; Scichilone N; Scioscia G; Spadaro G; Campisi R; Valenti G; Vatrella A; Crimi N
J Allergy Clin Immunol Pract; 2021 Dec; 9(12):4371-4380.e4. PubMed ID: 34419679
[TBL] [Abstract][Full Text] [Related]
11. Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study.
Padilla-Galo A; Moya Carmona I; Ausín P; Carazo Fernández L; García-Moguel I; Velasco-Garrido JL; Andújar-Espinosa R; Casas-Maldonado F; Martínez-Moragón E; Martínez Rivera C; Vera Solsona E; Sánchez-Toril López F; Trisán Alonso A; Blanco Aparicio M; Valverde-Monge M; Valencia Azcona B; Palop Cervera M; Nuevo J; Sánchez Tena J; Resler G; Luzón E; Levy Naon A
Respir Res; 2023 Sep; 24(1):235. PubMed ID: 37770889
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
13. High serum cytokine levels may predict the responsiveness of patients with severe asthma to benralizumab.
Watanabe S; Suzukawa M; Tashimo H; Ohshima N; Asari I; Imoto S; Kobayashi N; Tohma S; Nagase T; Ohta K
J Asthma; 2022 Aug; 59(8):1604-1612. PubMed ID: 34121592
[TBL] [Abstract][Full Text] [Related]
14. Real-life experience with benralizumab during 6 months.
Padilla-Galo A; Levy-Abitbol R; Olveira C; Valencia Azcona B; Pérez Morales M; Rivas-Ruiz F; Tortajada-Goitia B; Moya-Carmona I; Levy-Naon A
BMC Pulm Med; 2020 Jun; 20(1):184. PubMed ID: 32600318
[TBL] [Abstract][Full Text] [Related]
15. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy.
Fyles F; Nuttall A; Joplin H; Burhan H
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2715-2723. PubMed ID: 37245734
[TBL] [Abstract][Full Text] [Related]
17. Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
Portacci A; Campisi R; Buonamico E; Nolasco S; Pelaia C; Crimi N; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Scichilone N; Pelaia G; Crimi C; Carpagnano GE
ERJ Open Res; 2023 Sep; 9(5):. PubMed ID: 37908397
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
[TBL] [Abstract][Full Text] [Related]
19. Effect of Benralizumab on Mucus Plugs in Severe Eosinophilic Asthma.
Sakai N; Koya T; Murai Y; Tsubokawa F; Tanaka K; Naramoto S; Aoki A; Shima K; Kimura Y; Watanabe S; Hasegawa T; Kikuchi T
Int Arch Allergy Immunol; 2023; 184(8):783-791. PubMed ID: 37231966
[TBL] [Abstract][Full Text] [Related]
20. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
Chipps BE; Hirsch I; Trudo F; Alacqua M; Zangrilli JG
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):79-86. PubMed ID: 31626906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
